Skip to main content

Pharmaceutical Care for Cancer Outpatients

  • Chapter
  • First Online:

Abstract

In recent years, the number of oral anticancer agents (OACA), protein kinase inhibitors (PKI or “nibs”), in particular, has sharply increased. In the near future, the rise is likely to continue. OACA are used in the treatment of both common cancer types and a wide variety of less commonly occurring cancers and hematological malignancies. Due to the spreading use of OACA in cancer treatment pharmacists (and staff) of outpatient pharmacies are becoming more closely involved in the disease’s main treatment and directly interact with predominantly older cancer patients and other caregivers. Providing pharmaceutical care for cancer outpatients requires specific knowledge of cancer (drug) therapy, pharmacogenomics, contraindications, interactions of OACA with other drugs and food, side effects, and their management and patient education .Within the framework of a multidisciplinary team effort, the pharmacist dispensing OACA must assess the suitability of its use for the patient and address eventual problems that the treatment entails, notably with respect to supportive and current medication for chronic diseases. The pharmacist is also responsible for adequate patient counseling . Adherence to OACA treatment and effects brought about by OACA and co-medication require careful monitoring of the patient and his/her use of medication. Close collaboration with other healthcare providers, both in the case of prescribing OACA and co-medication and with respect to events occurring during the course of treatment as the result of disease progression, side effects or incorrect medication use, is the most appropriate way to resolve eventual problems and adequately adjust treatment. In the present chapter, the various steps of the pharmaceutical care process, conditions for its successful completion and the role of the pharmacist in it, are lined out and the main topics that have to be addressed during this process including the detection and management of drug interactions, the reporting and management of side effects, (non-) adherence and adherence supportive care, and last but not least, patient counseling are discussed. The basic approach is that pharmacists are partners of (primary care) physicians as they collaborate on a wide variety of care activities including the optimization of treatment, medication reconciliation, patient education , and medication safety.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Roskoski R. A historical overview of protein kinases and their small molecule inhibitors. Pharmacol Res. 2015;100:1–23.

    Article  CAS  Google Scholar 

  2. Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, et al. The target landscape of clinical kinase drugs. Science 2017;358:eaan4368.

    Article  Google Scholar 

  3. Leveque D, Delpuech A, Gourieux B. New anticancer agents: role of clinical pharmacy services. Anticancer Res. 2014;34:1573–8.

    CAS  PubMed  Google Scholar 

  4. Holle LM, Boehnke-Michaud L. Oncology pharmacists in health care delivery: vital members of the cancer care team. J Oncol Pract. 2014;10:e142–5.

    Article  Google Scholar 

  5. Dalby M. Current models of support from community pharmacists for patients on oral anticancer medicines. J Oncol Pharm Pract. 2017 September 26. https://doi.org/10.1177/1078155217732399.

  6. Timmers L, Boons CC, Verbrugghe M, van den Bemt BJ, Van Hecke A, Hugtenburg JG. Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. BMC Cancer. 2017;17:122–33.

    Article  Google Scholar 

  7. Boons CCLM, Timmers L, van Schoor NM, Swart EL, Hendrikse NH, Janssen JJWM, Hugtenburg JG. Patient satisfaction with information on oral anticancer agent use. Cancer Med. 2018;7:219–28.

    Article  CAS  Google Scholar 

  8. Cassidy J, Bissett D, Spence RAJ, Payne M, Morris-Stiff G. Oxford Handbook of Oncology (4th edition). Oxford: Oxford University Press; 2015.

    Book  Google Scholar 

  9. Ribed A, Escudero-Vilaplana V, Romero-Jimenez RM, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo-Saez M. Guiding pharmacist clinical interviews: a safety tool to support the education of patient treated with oral antineoplastic agents. Expert Opin Drug Safety. 2016;15:427–35.

    Article  Google Scholar 

  10. Broadfield L, Shaheen P, Rogez M, et al. Guidelines for outpatient cancer care by community pharmacists. CPJ. 2017;150:24–31.

    PubMed  Google Scholar 

  11. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12:1249–57.

    Article  Google Scholar 

  12. Bertholee D, Maring JG, Van Kuilenburg ABP. Genotypes affecting the pharmacokinetics of anticancer drugs. Clin Pharmacokinet. 2017;56:317–37.

    Article  CAS  Google Scholar 

  13. Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Leveque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two—targeted therapies. Eur J Cancer. 2014;50:2020–36.

    Article  CAS  Google Scholar 

  14. Boons CLM, Swart EL, Timmers L, Van de Ven PM, Jansen JJWN, Hugtenburg JG. Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia. BMC Cancer. 2014;14:247–52.

    Article  Google Scholar 

  15. Van Leeuwen RWF, Van Gelder T, Matthijsen RH, Janssen FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15:e315–26.

    Article  Google Scholar 

  16. Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Practice. 2014;10:e255–68.

    Article  Google Scholar 

  17. Timmers L1, Boons CC, Kropff F, van de Ven PM, Swart EL, Smit EF, et al. Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol 2014;53:259–267.

    Article  Google Scholar 

  18. Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21:354–76.

    Article  CAS  Google Scholar 

  19. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–32.

    Article  Google Scholar 

  20. Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jaqueline G. Hugtenburg .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hugtenburg, J.G., Timmers, L., Beckeringh, J.J. (2019). Pharmaceutical Care for Cancer Outpatients. In: Alves da Costa, F., van Mil, J., Alvarez-Risco, A. (eds) The Pharmacist Guide to Implementing Pharmaceutical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-92576-9_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92576-9_32

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92575-2

  • Online ISBN: 978-3-319-92576-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics